Univerzitetski Klinički Centar Srbije

Running trials

• Recruiting

  ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

  NCT07559903· Emory University· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Active, not recruiting

  ALIGN-ACS Pilot Study

  NCT07715474· HeartBeam, Inc.· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

  NCT07301736· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07155187· Phase 2/3· AbbVie· Source

• Recruiting

  PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

  NCT07142291· Phase 2· PhenoNet, Inc.· Source

• Recruiting

  A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

  NCT07155174· Phase 2· AbbVie· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Sanofi· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Recruiting

  A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

  NCT07059000· Phase 3· Kedrion S.p.A.· Source

• Recruiting

  Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07029581· Phase 2· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

  NCT07101939· Phase 2· Actimed Therapeutics Ltd· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients

  NCT06861361· Ceric Sàrl· Source

• Enrolling by invitation

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

  NCT06908226· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT06568939· Phase 2· AbbVie· Source

• Recruiting

  Drug-Eluting Balloon or Drug-Eluting Stent in Acute Myocardial Infarction: A Randomized Controlled Trial

  NCT06746233· Institute of Cardiovascular Diseases, Vojvodina· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

  NCT06719141· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

  NCT06568237· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Active, not recruiting

  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

  NCT06660394· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

  NCT06558279· Phase 3· argenx· Source

• Active, not recruiting

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06508658· Phase 3· Genmab· Source

• Recruiting

  A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT06428019· Phase 3· AbbVie· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

  NCT06475742· Phase 3· Viatris Innovation GmbH· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06468228· Phase 3· AbbVie· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease

  NCT05831085· Duk-Woo Park, MD· Source

• Recruiting

  A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

  NCT06056297· Phase 3· X4 Pharmaceuticals· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source

• Active, not recruiting

  A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

  NCT06245408· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06191744· Phase 3· Genmab· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

  NCT06063967· Phase 3· AbbVie· Source

• Recruiting

  Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression

  NCT06206369· Amsterdam UMC, location VUmc· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Summit Therapeutics· Source

• Active, not recruiting

  A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

  NCT05672576· Phase 3· Viatris Innovation GmbH· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Active, not recruiting

  Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

  NCT05705973· Terumo Europe N.V.· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  The Euro-CRAFT Registry

  NCT05805462· CoreAalst BV· Source

Showing 50 of 75.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease4 recruiting
• Lung cancer4 recruiting
• Alzheimer disease2 recruiting
• Epilepsy2 recruiting
• Heart failure2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Lupus (SLE)2 recruiting
• Multiple sclerosis2 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Asthma1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Depression1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• High blood pressure1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lewy body dementia1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Peripheral artery disease1 recruiting
• Schizophrenia1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Withdrawn

  POC for the Treatment of Subjects With Moderate AS Using Valvosoft® Non-Invasive Ultrasound Therapy

  NCT06650839· Cardiawave SA· Source

• Terminated

  Percutaneously Delivered Automated Continual Fluid Removal System in Patients With Advanced Diuretic-Resistant Heart Failure

  NCT06689553· Paragate Medical LTD· Source

• Completed

  A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

  NCT06664619· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Recruiting

  Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

  NCT06093672· Phase 3· Italfarmaco· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

  NCT05571137· Takeda· Source

• Terminated

  Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

  NCT05540665· Phase 2· Amgen· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

  NCT05776459· Phase 2· AudioCure Pharma GmbH· Source

• Completed

  A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.

  NCT05338086· Phase 3· mAbxience Research S.L.· Source

• Completed

  Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children

  NCT06361992· Phase 3· Catalysis SL· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Actelion· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

  NCT02100722· Stanford University· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Myeloproliferative neoplasms7 works · 5 trials
• Graves' disease and hyperthyroidism5 works · 0 trials
• Cushing's syndrome5 works · 0 trials
• Charcot-Marie-Tooth disease3 works · 0 trials